Systemic Sclerosis Treatment Market

Systemic Sclerosis Treatment Market

The global systemic sclerosis treatment market size is expected to reach US$ 3.8 Billion in 2022. The increasing development of first-in-class therapies by prominent companies is anticipated to augur well for the global market. As per Future Market Insights (FMI), the market is likely to be valued at US$ 7.1 Billion in 2032 and exhibit growth at a considerable CAGR of 5.9% in the forecast period from 2022 to 2032.

Systemic sclerosis is considered to be a rare autoimmune disorder that leads to atypical growth of connective tissues. These tissues become stiff and thick, which results in pain and swelling.

It also causes changes to the appearance and texture of the skin owing to high collagen production. It often leads to an immune response that destroys healthy tissues.

However, the disorder is not only confined to skin changes, but can also affect and individual’s kidneys, blood vessels, lungs, digestive system, heart, and muscles. The prevalence of this condition is projected to range from 50 to 300 cases per 1 million people.

Why is Off-label Drug Use Boosting the Systemic Sclerosis Treatment Market

Supplemental approvals for existing treatment options are likely to bolster the systemic sclerosis treatment market growth in future years. The increasing off-label use of numerous drugs approved for symptomatic indications, such as rheumatoid arthritis is also set to drive the market.

In addition to that, the rising prevalence of off-label drug use and the lack of curative therapies worldwide are expected to fuel the growth in this market. Many renowned companies are aiming to submit their applications for the approval for new drug therapies, which is another crucial factor that is estimated to aid the growth.

Which Factors May Restrain the Systemic Sclerosis Treatment Market Growth

The lack of validated results associated with various treatment options of systemic sclerosis may hinder the growth in this market. Many clinical trials that were conducted to evaluate systemic scleroderma therapeutics failed due to certain issues, which is likely to decline the demand for systemic sclerosis treatment options.

How is the North America Systemic Sclerosis Treatment Market Faring

North America is anticipated to generate the largest systemic sclerosis treatment market share of about 18.5% in the forecast period. This growth is attributable to the availability of recently developed immunosuppressants and the presence of a favorable reimbursement scenario across the U.S.

It is estimated that the prevalence of systemic sclerosis is 20 cases per million population in the U.S. The high healthcare expenditure in this country is also likely to drive the regional market. Besides, the presence of a large number of significant pharmaceutical companies in the U.S. is set to bode well for the North America market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What is the Europe Systemic Sclerosis Treatment Market Outlook

The increasing usage of biosimilars and generics in the U.K., Italy, and Germany for the treatment of systemic scleroderma is likely to push sales of systemic sclerosis treatment options across Europe. The increasing launch of small molecules and cutting-edge biologics for the treatment of systemic sclerosis is another vital factor that is projected to drive the regional market.

Furthermore, the high unmet medical needs are expected to create new growth opportunities for key players operating in Europe. The surging popularity of immunosuppressants owing to their high efficacy, as compared to mycophenolate mofetil, methotrexate, and methotrexate is likely to aid growth in this region.

Market Competition

Some of the leading companies operating in the global systemic sclerosis treatment market include Sanofi, Actelion Pharmaceuticals, Inc., Pfizer, Inc., Gilead Sciences, Inc., Cytori Therapeutics, Inc., Eli Lilly, Bayer AG, Boehringer Ingelheim, and Asta Pharma among others.

The market consists of various pharmaceutical companies that are currently striving to acquire a larger market share. To do so, they are engaging in partnerships, acquisitions, and mergers with other key players. Meanwhile, some of the other companies are increasingly focusing on launching immunosuppressants for the treatment of scleroderma induced ILD and PAH.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Scope of Report

Key Segments Profiled in the Systemic Sclerosis Treatment Industry Survey

By Therapeutics:

• Corticosteroids
• Immunosuppressant
• Non-steroidal Anti-inflammatory Drugs
• Blood Pressure Medication
• Light Therapy
• Nitroglycerin Ointment
• Others

By Disease Type:

• Limited Cutaneous Systemic Sclerosis
• Diffuse Cutaneous Systemic Sclerosis

By End User:

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• Japan
• Middle East and Africa